BNGO · XBRL financial data

Bionano Genomics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BNGO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue from contracts with customers	8,503	17,981	27,802	36,116	30,776	28,508
Cost of goods and services sold	5,730	14,107	21,857	26,550	30,396	15,323
Research and development	10,256	22,485	49,047	54,032	24,803	11,374
Selling, general and administrative	31,068	58,490	88,596	93,499	51,855	35,150
Operating income (loss)	(38,551)	(77,101)	(131,698)	(215,245)	(103,983)	(33,339)
Interest income	—	400	1,500	3,300	1,500	1,000
Interest expense	2,519	927	298	5,119	—	—
Other income (expense)	(7)	(59)	(223)	3,449	(10,102)	5,900
Income tax expense (benefit)	29	(5,717)	1,884	62	33	67
Net income (loss)	(41,106)	(72,435)	(132,596)	(232,493)	(112,017)	(26,395)
Earnings per share, basic‡ USD per share	—	(155.69)	(275.45)	(407.78)	(5,277.25)	(4.85)
Earnings per share, diluted‡ USD per share	—	(155.69)	(275.45)	(407.78)	(5,277.25)	(4.85)
Weighted average shares, basic‡ thousands of shares	—	462	483	570	21	5,445
Weighted average shares, diluted‡ thousands of shares	—	462	483	570	21	5,445

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (August 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-59.880239520958085 stock split (January 2025); filings made before it reported them unadjusted.
† Share count changed about 1/18 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 221x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BNGO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	38,449	24,571	5,091	17,948	9,173	2,990
Marketable securities	0	226,041	108,095	48,823	302	16,279
Accounts receivable	2,775	4,934	7,022	9,319	4,752	5,200
Inventory	3,316	12,387	29,761	27,602	13,276	7,828
Prepaid and other current assets	2,250	4,481	7,329	6,019	3,141	5,203
Total current assets	46,789	272,414	157,298	140,118	39,489	45,386
Property and equipment, net	4,910	10,318	18,029	23,345	19,219	14,847
Right-of-use asset	0	6,691	7,222	5,633	1,804	3,217
Goodwill	7,173	56,160	77,289	0	—	—
Total assets	60,450	377,100	307,502	214,404	76,670	73,584
Accounts payable	2,930	9,696	12,534	10,384	6,962	5,590
Accrued liabilities	5,599	9,694	10,552	8,089	5,641	5,460
Current portion of long-term debt	0	—	—	—	—	—
Total current liabilities	8,944	21,840	35,884	100,028	37,344	22,942
Long-term debt	16,326	0	—	—	—	—
Lease liability, non-current	0	5,288	5,504	3,590	145	2,489
Total liabilities	25,367	39,982	58,104	118,247	41,295	29,160
Accumulated deficit	(143,684)	(216,119)	(348,715)	(581,208)	(693,225)	(719,620)
Total stockholders' equity	35,082	337,118	249,398	96,157	35,375	44,424
Total liabilities and equity	60,450	377,100	307,502	214,404	76,670	73,584
Common shares outstanding (cover page)‡ thousands of shares	465	484	511	913	50	11,092

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (August 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-59.880239520958085 stock split (January 2025); filings made before it reported them unadjusted.
† Share count changed about 1/18 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 221x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BNGO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(41,106)	(72,435)	(132,596)	(232,493)	(112,017)	(26,395)
Stock-based compensation	1,554	9,719	22,417	15,178	9,736	4,534
Depreciation and amortization	1,480	3,351	9,621	13,708	14,022	9,527
Net cash from operating activities	(38,314)	(71,927)	(124,816)	(125,181)	(68,922)	(16,345)
Purchases of property and equipment	0	—	—	—	—	—
Net cash from investing activities	(2,450)	(278,062)	82,767	24,158	73,839	(12,747)
Proceeds from issuing common stock	—	—	23,128	57,697	44,433	31,098
Proceeds from issuing equity	—	—	—	57,800	21,400	—
Net cash from financing activities	61,902	336,111	23,007	113,815	(13,685)	24,039
Net change in cash	21,137	(13,878)	(19,080)	12,857	(8,775)	(5,064)

† Share count changed about 1/18 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 221x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Bionano Genomics	3,730	8,171	(4,670)*	11.8M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Focus Universal	1,600	675	(741)*	702,745	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Precipio	3,075	7,021	660*	1.8M	—	Q2 FY26 10-QJun 30, 2026
Harvard Bioscience	6,503	22,727	325*	4.6M	—	Q2 FY26 10-QJun 30, 2026
Syntec Optics Holdings	14,047	8,274	(299)*	40.3M	47.0 quarters	Q2 FY26 10-QJun 30, 2026
MultiSensor AI Holdings	21,005	1,695	(2,392)*	2.2M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Radnostix	1,196	2,672	(614)*	529.2M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Optex Systems Holdings	6,175	9,729	2,323*	7.0M	—	Q3 FY26 10-QJun 28, 2026
Electro Sensors	10,756	not reported	68	3.5M	—	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.